LONDON — European regulators on Thursday detailed their demands that Illumina divest the cancer diagnostics firm Grail, the latest fallout from the sequencing giant’s troubled 2021 acquisition.
The move was just the most recent regulatory action against the deal. The European Commission in September 2022 ruled that the purchase violated antitrust rules, and Thursday’s order spelled out how the commission thought the deal’s unraveling should occur.
The commission in July also issued a $460 million fine to Illumina for closing the $8 billion deal before getting antitrust clearance.
